Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBITDA (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBITDA for 4 consecutive years, with -$27.5 million as the latest value for Q4 2025.

  • For Q4 2025, EBITDA rose 57.97% year-over-year to -$27.5 million; the TTM value through Dec 2025 reached -$127.8 million, up 41.2%, while the annual FY2025 figure was -$127.8 million, 41.2% up from the prior year.
  • EBITDA was -$27.5 million for Q4 2025 at Day One Biopharmaceuticals, down from -$24.3 million in the prior quarter.
  • The five-year high for EBITDA was $29.6 million in Q3 2024, with the low at -$114.8 million in Q2 2024.
  • Historically, EBITDA has averaged -$43.6 million across 4 years, with a median of -$41.9 million in 2022.
  • The largest annual shift saw EBITDA soared 157.61% in 2024 before it tumbled 181.83% in 2025.
  • Over 4 years, EBITDA stood at -$42.7 million in 2022, then tumbled by 39.24% to -$59.5 million in 2023, then dropped by 9.77% to -$65.3 million in 2024, then surged by 57.97% to -$27.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$27.5 million in Q4 2025, -$24.3 million in Q3 2025, and -$35.0 million in Q2 2025.